Sutro Biopharma STRO Deferred Offering Cost Included In Accounts Payable And Accrued Expenses
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept stro:DeferredOfferingCostIncludedInAccountsPayableAndAccruedExpenses.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's deferred offering cost included in accounts payable and accrued expenses.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's deferred offering cost included in accounts payable and accrued expenses?
- Sutro Biopharma (STRO) reported deferred offering cost included in accounts payable and accrued expenses of $435K in Q1 2026.